CLINICAL_TRIALS
withdrawal
· 2015-09-01
Clinical Trial Update: Entecavir Plus Adefovir in Lamivudine-Resistant Patients [Phase 4]
Summary
A Phase 4 trial evaluating the combination of entecavir and adefovir for lamivudine-resistant chronic hepatitis B has been withdrawn.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Bristol-Myers Squibb | Conditions: Hepatitis B, Chronic | Phase 4 | Status: WITHDRAWN